AgomAb Therapeutics NV (NASDAQ:AGMB) Given Average Rating of “Moderate Buy” by Analysts

Shares of AgomAb Therapeutics NV (NASDAQ:AGMB) have earned an average recommendation of “Moderate Buy” from the five research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $32.75.

Separately, HC Wainwright began coverage on AgomAb Therapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $35.00 price target on the stock.

AgomAb Therapeutics Stock Performance

Shares of AgomAb Therapeutics stock opened at $11.64 on Friday. The company’s 50-day simple moving average is $11.71. AgomAb Therapeutics has a one year low of $8.75 and a one year high of $17.82.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.